Quantum Biopharma (QNTM) Accounts Payables (2018 - 2026)

Quantum Biopharma has reported Accounts Payables for 9 years, with the latest figure at $3.6 million in Q1 2026.

• Quarterly Accounts Payables rose 52.37% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 52.37% YoY) and the FY2025 annual result came in at $4.2 million, down 4.13% from the prior year.
• Accounts Payables fell to $3.6 million in Q1 2026 per QNTM's latest filing, from $4.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $7.9 million in Q1 2022 and troughed at $2.4 million in Q1 2025.
• A 5-year average of $5.0 million and a median of $4.4 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables tumbled 42.99% in 2023, then soared 52.37% in 2026.
• Over 5 years, Accounts Payables stood at $7.1 million in 2022, then tumbled by 47.92% to $3.7 million in 2023, then advanced by 17.84% to $4.4 million in 2024, then fell by 4.13% to $4.2 million in 2025, then retreated by 14.13% to $3.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.6 million, $4.2 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.